Montaka Global’s Moderna MRNA Stock Holding History

Montaka Global’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.4M	Sell	19,950 -108	-0.5%	-$5.59K	0.79%	19
2026 Q1	$1.02M	Buy	20,058 +6,483	+48%	+$302K	0.61%	20
2025 Q4	$400K	Buy	+13,575	New	+$369K	0.19%	18

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Montaka Global's MRNA Position: Q2 2026 in Review

Montaka Global reduced its Moderna (MRNA) stake by 0.54% in Q2 2026, selling an estimated $5.59K and leaving 19,950 shares worth $1.4M. The position accounts for 0.79% of the portfolio, ranked #19.

Montaka Global first reported a position in MRNA in Q4 2025 and has held it in 3 quarters since. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Montaka Global held 19,950 shares of Moderna worth $1.4M as of Q2 2026.
Montaka Global sold 108 Moderna shares in Q2 2026, an estimated $5.59K.
Moderna made up 0.79% of Montaka Global's portfolio in Q2 2026, its #19 holding.
Montaka Global first reported a position in Moderna in Q4 2025 and has held it in 3 quarters since.
780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Montaka Global's 13F filing for Q2 2026, filed 11 Aug 2026.